Background
==========

Development of malignant B-cell lymphomas after organ transplantation is a significant complication arising as a side effect of the immunosuppression required for successful graft survival. The oncogenic Epstein-Barr virus (EBV) is the etiologic agent in the posttransplant lymphoproliferative disorder (PTLD) and AIDS related immunoblastic lymphomas (ARL) \[[@B1]\]. The reported overall mortality for PTLD often exceeds 50% \[[@B2],[@B3]\]. The prognosis for PTLDs occurring after bone marrow transplantation is even worse \[[@B4],[@B5]\]. Male patients with the rare inherited X-linked lymphoproliferative syndrome, showing specific immune defect against EBV infection, also often succumb to EBV induced malignant lymphomas \[[@B6]\].

EBV is a ubiquitous human herpesvirus that persists for life. Primary EBV infection can lead to mononucleosis (IM) in adolescence and in adults, manifested by a massive expansion of B cells. EBV-encoded transformation-associated proteins drive the proliferation of B lymphoblasts in IM, in PTLDs and in immunodeficiency syndrome-associated immunoblastic lymphomas. The EBV transformed cells express nine latency-associated viral proteins: EBNA1-6, LMP-1, -2A and -2B. This latency program is referred to as the type III latency. The same latency program is present in the *in vitro*proliferating lymphoblastoid cell lines (LCLs), generated by infection of normal human B cells with EBV. The fraction of B cells that is susceptible to *in vitro*transformation can be anything between 10% and 100% \[[@B7]\].

EBV drives the proliferation of human B cells *in vitro*and during primary infection *in vivo*. Strong T cell-mediated immune responses have been documented against EBV encoded latent proteins and a wide range of HLA class I molecules with EBV originated peptide epitopes have been identified \[[@B8]-[@B10]\]. EBV associated lymphoproliferative disease can develop only in the absence of a competent cytotoxic T cell immune surveillance. EBV associated lymphoproliferative disease may disappear upon treatment restoring the immune response against EBV-infected B cells.

Historically LCLs were often regarded as non-tumorigenic in immunosupressed mice upon subcutaneous inoculation, especially in comparison with highly tumorigenic Burkitt\'s lymphomas. However intraperitoneal inoculation regularly leads to development of generalized lymphomas with multiorgan involvement. SCID mice inoculated intraperitoneally with peripheral blood lymphocytes (PBL) from EBV-seropositive donors or with human LCLs, develop EBV-induced human lymphoproliferations within a few weeks. These lymphomas are classified as immunoblastic lymphomas, often with plasmacytoid features \[[@B11]\]. Histologically the PBL derived human-SCID tumors very much resemble the EBV positive large cell lymphomas of immunosuppressed patients \[[@B12]\]. The tumors of the immunocompromised patients or the experimental tumors growing in immunodefective mice as well as the *in vitro*growing LCLs show very similar phenotypes. All three express the same spectrum of cell surface markers, B cell activation antigens and adhesion molecules. All three have normal karyotype and show identical viral gene expression patterns.

The risk of PTLD has been found to depend upon the type of the transplanted organ, the immunosuppressive regimen, the age, the underlying illness and the EBV status of the recipient at the time of transplantation. The estimated incidence of PTLD ranges from 1--4% after renal transplantation to 19% after intestinal transplantation. In bone marrow allograft recipients PTLD is relatively uncommon (1%) \[[@B13],[@B14]\] except for when certain high risk regimes, such as in vitro T-cell depletion (TCD) are used, when the risk may rise to 30%\[[@B4],[@B15]\] PTLD following allogenic stem cell transplantation usually derives from donor lymphocytes. The risk of PTLD is greater if the host is EBV-seronegative at the time of transplantation and/or if there is a mismatch between the donor and recipient HLA types \[[@B1]\].

No controlled studies have been performed in the management of PTLD and most of the recommendations for therapy come from small cohorts at single institutions \[[@B1]\]. The relative importance of T cell impairment, EBV and clonal proliferation has led to the following strategies: reduction of immunosuppression or prophylactic restoration of T-cell immunity \[[@B16]\], antiviral therapy and chemotherapy. Reducing the immunosuppression leads to complete and durable remission of PTLD \[[@B17]\] for 23--50% of patients after organ transplantation (SOD) but will not be efficient in the BMT setting. Reduction of immunosuppression is frequently the first therapeutic step, and patients who have had organ rejection have a much poorer prognosis.

For secondary EBV lymphomas post BMT none of the above regimens will suffice, except when specifically restoring EBV specific immunity \[[@B16]\]. Anti-B-cell monoclonal antibodies are an effective therapy for PTLD. A combination of anti CD21 and anti-CD24 antibodies were used. However these antibodies are not commercially available and interest has therefore recently turned towards Rituximab, a humanized monoclonal antibody against the pan-B cell marker CD20. The response rate of Rituximab treatment is 65% with a relapse rate of 18% \[[@B18],[@B19]\].

In cases that are not responding to the above mentioned therapy, chemotherapy is used as the second or third line of option.

The most frequently used chemotherapy protocols are the anthracycline based CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and VAPEC-B (doxorubicin, etoposide, cyclophosphamide, methotrexate, bleomycin, and vincristine) \[[@B20]\]. In the study of Muti *et al.*17 of 40 PTLD patients were treated with a combination of reduced immunosuppression and chemotherapy (CHOP, VACOP-B -- cyclophosphamide, vincristine, bleomycin, prednisolone, with increasing doses of doxorubicin and etoposide- or DHAP -cisplatinum, cytosine-arabinoside, dexamethasone) \[[@B21]\]. Remission rate for anthracycline-based combination therapy is 69%.

PTLD patients are exposed to a high mortality risk due to chemotherapy treatment related toxicity \[[@B1]\].

The side effects of a drug are the limiting factor in determining the dose. Increasing the dose of a drug leads to a more frequent appearance of side effects. Chemotherapeutic agents can also compromise the survival of the graft. Drugs that are effective even at low doses could therefore, not only give fewer side effects, but also provide a better graft survival.

The aim of this study was to find the most effective cytotoxic drugs against EBV-induced lymphoproliferations. We carried out over 6500 cell survival and proliferation assays, on single cell level, in order to establish the pattern of *in vitro*efficacy of the most commonly used cytotoxic drugs against EBV-transformed lymphoblastoid cells.

Methods
=======

Cell lines and culture conditions
---------------------------------

17 lymphoproliferative cell lines (LCLs) were used in the present study. 980215, 031016, 040113, 051018, JAK, LP, MIN, AF, GK, FUR, HA, VMB were established by *in vitro*infection of normal B lymphocytes, from different healthy donors, with the B95.8 strain of EBV. These cell lines were expanded in IMDM (Sigma) medium supplemented with 10% fetal calf serum (FCS). LSspontan is a spontaneous LCL established from a healthy donor. IARC171 was established using B95.8 virus infection of normal lymphocytes from a patient with Burkitt\'s lymphoma. TR was established from B cells of an XLP patient, with deletion in the SAP gene. The cell line IB4 contains an integrated EBV genome.

During the time of experiment the LCLs were cultured in IMDM (Sigma) supplemented with 20% FCS (Sigma), 100 mmol L-glutamine (Sigma) and 80 μg/ml gentamicin (Sigma). Cell suspensions were grown in a humidified incubator at 37°C in an atmosphere containing 5% CO~2~. Cell counts were adjusted to an optimal concentration of 1 × 10^6^cells/ml and the cells were fed twice a week. The absence of mycoplasma contamination was assured by regular monitoring with Hoechst 33258 staining.

Drugs
-----

For the *in vitro*drug sensitivity test 29 drugs were used (summarized in Table [1](#T1){ref-type="table"}). All the drugs were dissolved in 50% dimethyl sulfoxide (DMSO) and printed on 384 well plates, using a high density metal pin array (with 50 nl replica volumes) in Biomek 2000 fluid dispenser robot (Beckman). The same robot was used to generate the drug masterplates containing the triplicates of four different drug dilutions using a single tip automatic dispenser head.

The highest drug concentration was selected as the physicochemical maximally achievable drug concentration at 600 times dilution (50 nl drug in 30 μl suspension assay volume)

The Ratio of Maximum Achieved Plasma Concentration (RMAPC) was determined for each drug concentration in order to compare the *in vitro*tested concentrations to the *in vivo*maximally achieved plasma concentration (Cmax) levels.

RMAPC was calculated according to the following equation:

RMAPC = *in vitro*tested concentration/Cmax

In vitro drug sensitivity assay
-------------------------------

In vitro drug sensitivity of LCLs was assessed using a 3-day cell culture on microtiter plates. 28 drugs were tested, each at 4 different concentrations in triplicates on 384-well plates (Greiner). Each well was loaded with 30 μl cell suspension containing 3000 cells. After three days of incubation the live and dead cells were differentially stained using fluorescent VitalDye (Biomarker, Hungary). The exact number of live and dead cells was determined using a custom designed automated laser confocal fluorescent microscope (a modified Perkin-Elmer UltraView LCI system) at the Karolinska Institute visualization core facility (KIVIF). The images were captured using the computer program QuantCapture 4.0 and the live and dead cells were identified and individually counted using the program QuantCount 3.0. Both programs were developed at the KIVIF using OpenLab Automator programming environment (Improvision). 15 control wells, that were used to determine the control cell survival (CCS), contained cells with only culture medium and 50 nl DMSO without drugs, 5 wells contained cells with culture medium alone. Comparing the two types of control wells no toxic effect of DMSO could be seen. Mean cell survival (MCS) was determined from the average of cell survival of all 17 LCLs.

Results
=======

Comparison of the drug sensitivity pattern of the different LCLs
----------------------------------------------------------------

The 17 different LCLs that were tested in the present study represent a large variety of cells with different origins and *in vitro*history. The investigation included cell lines with several years of continuous *in vitro*culturing along with freshly established transformed B-cell cultures of only 3 weeks of age. Many of the lines were transformed by the B95-8 strain of EBV and some of them were spontaneous outgrowths driven by the donors own virus. Among the lines, we had LCLs from healthy donors, from XLP patients or lines established from the normal B-cells of Burkitt\'s lymphoma patients. We tested lines with both episomal and integrated EBV genome.

Remarkably, the LCLs of different origins showed a very similar sensitivity pattern against the different drugs. This phenomenon is illustrated in Figure [1](#F1){ref-type="fig"}, which summarizes the survival curves of all 17 LCLs against the four different concentrations of epirubicin. Each individual thin curve represents the average of three independent measurements. The thick line is the mean of all curves, the Mean Cell Survival (MCS). The grey shaded area marks the ± standard deviation (SD). Figure [2](#F2){ref-type="fig"} summarizes the Mean Cell Survival curve along with the standard deviations for 28 drugs again emphasizing the very similar response of the different cell lines. The values for MG132 are represented only in Table [2](#T2){ref-type="table"}.

Identification of highly effective and non-effective drugs
----------------------------------------------------------

The starting concentrations of the dilution series (1×, 4×, 16×, 64×) for the individual drugs were initially determined based on the solubility of the different agents. To make the cell survival data comparable with each other, we first compiled the known Maximum Achieved Plasma Concentration data (Cmax) for all 28 drugs stated from the literature (Table [1](#T1){ref-type="table"}-column 5). Dividing the actual drug concentrations in the dilution series with the Cmax of the particular drug yielded the Ratio of Maximum Achieved Plasma Concentration (RMAPC). The calculated values of RMAPC for all the drugs are summarized in Table [2](#T2){ref-type="table"} along with MCS and ± SD values. Plotting the cell survival against the RMAPC values allowed a direct comparison of the effectiveness of different drugs. Figure [3](#F3){ref-type="fig"} shows the comparison of the effectiveness of the members of three different drug families: the anthracyclines, vinca alcaloids and taxans. Figure [4](#F4){ref-type="fig"} summarizes the mean cell survival curves for all the drugs along a common RMAPC axis. Based on their effectiveness on LCLs, we have divided the drugs into three different groups:

Group 1: The drugs were considered to be highly effective if the mean cell survival (MCS) was below 30% at RMAPC 0.3 or below that.

Group 2: The drug was partially effective if MCS was under 60% and RMAPC was between 0.3 and 1.

Group 3: The drug was ineffective, e.g. the LCLs were resistant to the drug, if MCS was above 60% or RMAPC was above 1.

We found that the four most effective drugs against LCLs were: **vincristine, paclitaxel, methotrexate and epirubicin**(Group 1).

Gemcitabin, cytosine-arabinoside, doxorubicin, fluorouracil, dactinomycin, docetaxel, daunorubicin, etoposide, vinorelbine was rated as partially effective (Group 2.)

Most LCLs were resistant to cyclophosphamide, asparaginase, topotecan, oxaliplatin, bleomycin, 6-mercaptopurin, hydroxyurea, cladribine, chlorambucil, carboplatin, bortezomib, cytarabine, prednisolone and vinblastine (Group 3). Almost no drug response could be seen with oxaliplatin, bleomycin, cyclophosphamide, asparaginase, hydroxyurea and ifosphamide whereas vinblastine, chlorambucil, prednisolone and topotecan were effective, but only at very high concentrations, well above the maximum achievable plasma concentrations.

Although the Group 3 drugs were not effective against LCLs, these drugs show concentration dependent growth inhibitory effects on other cell lines or primary tumors (data not shown).

No RMAPC could be determined for streptozocin because no pharmacokinetical trials with established Cmax plasma levels were found. RMAPC was also not available for MG132 because it has not been used clinically. Streptozocin had no effect on survival at the concentrations used in the study. Although at the highest concentrations the proteasome inhibitor MG132 effectively decreased the survival of the cells, its clinically licensed functional homologue, bortezomib, was not effective.

An alternative way to calculate relationship between the *in vitro*drug concentrations and the *in vivo*used values is to use the area under curve (AUC) values of the individual drugs. To compare AUC values with the RMAPC data the following formula was used:

*in vitro*used concentration (μg/ml) × 72 h/AUC (μgxh/ml) *in vivo*.

*In vivo*AUC levels from the literature are summarized in Table [1](#T1){ref-type="table"}. Using the formula for representing the mean cell survival curves for all the drugs along a common \"ratio of AUC\" axis, carboplatin, methotrexate and dactinomycin showed higher efficacy in comparison to RMAPC figures whereas the sensitivity order for the other drugs or for the group classifications did not change.

Discussion
==========

The presented data suggest that many EBV transformed B-cell lines share a common cytotoxic drug sensitivity profile independent of their origin. This profile does not change even after many years of *in vitro*culturing. EBV appears to be the necessary and sufficient etiological agent behind the malignant immunoblastic B-cell lymphoproliferations in immunosuppressed patients. In all these cases the EBV encoded, latency associated viral proteins drive the cell proliferation without any obvious need for additional genetic changes. The phenotype of these tumors closely resembles the *in vitro*growing LCLs and the experimentally induced tumors that appeared upon intraperitoneal implantation of LCLs into SCID mice \[[@B11]\]. Considering the phenotypic and karyotypic stability of EBV transformed B-cells, our data raises the hope that PTLDs, AIDS associated CNS lymphomas and XLP associated lymphoproliferations may show similar patterns of drug sensitivity as the ones that we have established in the present study on a cohort of diverse LCLs.

Sugimoto et al. suggested that EBV mediated transformation is a two step process where, after prolonged passage, the cells may become aneuploid, accumulate p53 mutations, down regulate the p16/retinoblastoma protein pathway and become tumorigenic upon subcutaneous inoculation into nude mice \[[@B7]\]. Some of the cell lines that we have examined were kept in continuous culture over five years (IARC171, LSspontan, 980215). These cells are still euploid and show low soft agar clonability. The oldest line IARC171, has wild type p53, is non-tumorigenic upon subcutan inoculation but produces generalized immunoblastic lymphomas in SCID mice after intraperitoneal inoculation. The findings that PTLD can arise very rapidly in post-transplant patient together with the data that freshly EBV infected B-cells can grow into generalized immunoblastic lymphomas within a few weeks, implies that the development of PTLD does not require aneuploidy. Sawada *et al.*reported that LCLs with negative or low telomerase activity and normal karyotypes are more sensitive against certain drugs, than LCLs with a high telomerase activity and abnormal karyotypes \[[@B22]\]. This data together with our present findings may suggest that rapidly emerging PTLDs may show different drug sensitivity pattern from EBV positive aneuploid diffuse large cell B-cell lymphomas that arise for example in AIDS patients in sub-Saharan Africa.

Our data shows that euploid LCLs are particularly sensitive for anti-microtubule drugs and anthracyclines. Although all LCLs showed a dose dependent increase of cytotoxicity when treated with different members of these two drug families, only vincristine and paclitaxel as well as epirubicin and doxorubicin were considered to be effective when the used *in vitro*drug concentrations were compared to the maximum achievable plasma concentrations.

Alkylating agents, such as cyclophosphamide and ifosphamide were not effective on LCLs. This might be explained by the fact that both of these compounds are pro-drugs that have to be converted into active metabolites by the liver *in vivo*. Prednisolone was active but only in very high concentrations.

Conclusion
==========

Vincristine and methotrexate are included in the frequently used CHOP and VAPEC-regimes, but no data could be found for the clinical use of epirubicin and paclitaxel for the treatment of PTLD or other EBV induced lymphoproliferations. Our results suggest that the inclusion of epirubicin and paclitaxel into chemotherapy protocols against PTLD may be justified.
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![**Drug sensitivity pattern of 17 lymphoblastoid cell lines for epirubicin**. The mean value of survival of LCLs is represented by the black curve, ± SD value is marked with grey. 1× : highest concentration, 16×: 16 times dilution of the highest concentration etc.](1471-2407-6-265-1){#F1}

![**Mean values and standard deviations of drug sensitivity of 17 lymphoblastoid cell lines for 28 different cytostatic drugs**. y axis: fraction of surviving cells 0--100% x axis: drug dilutions (1× represents the highest concentration).](1471-2407-6-265-2){#F2}

![Drug sensitivity of LCLs for anthracyclines, vinca alkaloids and taxans.](1471-2407-6-265-3){#F3}

![**Drug sensitivity mean values of 17 lymphoblastoid cell lines plotted against the Ratio of Maximum Achieved Plasma Concentration (RMAPC) values**. The different drug families are labelled with different colours. The highly effective (Group 1) and partially effective (Group 2) drugs are identified.](1471-2407-6-265-4){#F4}

###### 

Used drugs, Cmax, AUC levels

  **Drug groups**          **Drug name**      **Brand name, company**            ***In vitro*used concentrations (μg/ml)**   **Cmax Value (μg/ml)**   ***In vivo*dose (Cmax)**   **AUC (μg × h/ml)**   ***In vivo*dose (AUC)**   **Reference**
  ------------------------ ------------------ ---------------------------------- ------------------------------------------- ------------------------ -------------------------- --------------------- ------------------------- ------------------------------------------------------------
  anthracyclines           epirubicin         Epirubicin Meda, Meda              0.026--1.66                                 9                        120 mg/m^2^                2.412                 90 mg/m^2^                (Fogli et al. 2002) \[23\]
                           daunorubicin       Cerubidin^®^, Aventis Pharma       0.065--4.166                                0.49                     0.95 mg/kg in 45 min       1.2786                1.5 mg/kg                 (Andersson et al. 1979) \[6\]
                           doxorubicin        Doxorubicin Teva, Teva             0.026--1.66                                 0.93                     50 mg/m^2^                 0.82464               50 mg/m^2^                (Toffoli et al. 2004) \[24\]
  epipodophyllotoxin       etoposide          Sigma                              0.325--20.833                               2.5                      53 mg/m^2^/day             5.06                  100 mg/m^2^/day           (Minami et al. 1995) \[25\] (Gruber et al.1995) \[26\]
  camptothecins            topotecan          Hycamtin^®^, GlaxoSmithKline       0.052--3.33                                 0.0084                   2.3 mg/m^2^/day            0.0196                1.2 mg/m^2^/day           (Gerrits et al. 1999) \[27\]
  taxanes                  paclitaxel         Taxol, Orifarm                     0.078--5                                    3.38                     175 mg/m^2^by 3 h          13.49                 175 mg/m^2^               (Fogli et al. 2002) \[23\]
                           docetaxel          Taxotere^®^, Aventis Pharma        0.52--33.33                                 2                        60 mg/m^2^                 3.326                 85 mg/m^2^                (Rischin et al. 2002) \[28\]
  vinca alkaloids          vincristine        Vincristine Mayne, Mayne Pharma    0.0065--0.416                               0.37                     1.4 mg/m^2^                0.182                 1.32 mg/m^2^              (Terashi et al. 2000) \[29\] (Desai et al. 1982) \[30\]
                           vinblastine        Velbe^®^, STADApharm               0.013--0.833                                0.005                    1.5 mg/m^2^by 24 h         0.218                 1.7 mg/m^2^               (Stewart et al. 1983) \[31\] (Bates et al.) \[32\]
                           vinorelbine        Navelbine^®^, Pierre Fabre         0.13--8.33                                  0.83                     200 mg/week                0.899                 80 mg/m^2^/week           (Zhou et al. 1991) \[33\] (Freyer et al. 2003) \[34\]
  platinum analogs         carboplatin        Carboplatin Mayne, Mayne Pharma    0.13--8.33                                  0.046                    360 mg/m^2^                348000                360 mg/m^2^               (Ghazal-Aswad et al. 1996) \[35\]
                           oxaliplatin        Eloxatin, Sanofi-Synthelabo        0.065--4.166                                3.2                      130 mg/m^2^                71.5                  130 mg/m^2^               (Gamelin et al. 1997) \[36\] (Graham et al. 2000) \[37\]
  antifolate               methotrexate       Methotrexate Pharmacia, Pfizer     0.325--20.833                               363                      8--12 g/m^2^               13200000              12 g/m^2^                 (Bacci et al. 2006) \[38\] (Crews et al. 2004) \[39\]
  purin antagonists        6-mercaptopurine   Sigma                              1.085--69.44                                2                        2.5 mg/kg oral dose        0.2587                85 mg/m^2^                (Chan et al. 1989) \[26\]
                           cladribine         Leustatin, Janssen-Cilag           0.013--0.833                                0.0356                   5 mg/m^2^                  0.1541                5 mg/m^2^                 (Albertioni et al. 1998) \[40\]
  pyrimidine antagonists   fluorouracil       Fluorouracil Mayne, Mayne Pharma   0.65--41.66                                 55.4                     400 mg/m^2^                11.59                 400 mg/m^2^               (Casale et al. 2004) \[41\]
                           cytarabine         Cytarabine Pfizer, Pfizer          1.302--83.33                                10.8                     3 g/m^2^                   523.4                 1 g/m^2^                  (DeAngelis et al. 1992) \[42\] (Gruber et al. 1995) \[26\]
                           gemcitabine        Gemzar, Orifarm                    0.781--50                                   22.3                     1000 mg/m^2^               9.3                   1000 mg/m^2^              (Fogli et al. 2002) \[23\]
  antitumor antibiotics    bleomycin          Bleomycin Baxter, Baxter           0.39--25\*                                  0.19\*                   30 IU/day                  0.089                 8 IU/kg/day               (Broughton et al. 1977) \[43\] (Peng et al.1980) \[44\]
                           dactinomycin       Cosmegen^®^, MSD                   0.006--0.416                                0.1                      1.5 mg/m^2^                300                   1.5 mg/m^2^               (Veal et al. 2005) \[45\]
  protease inhibitors      bortezomib         Velcade^®^, Janssen-Cilag          0.013--0.833                                0.08                     1.45 mg/m^2^               0.0438                1.45 mg/m^2^              (Papandreou et al. 2004) \[46\]
                           MG132              Sigma                              0.13--8.33                                  **\#**                                                                                              
  alkylating agents        cyclophosphamide   Sendoxan, Baxter                   0.52--33.33                                 37.2                     50 mg/kg                   367                   50 mg/kg                  (Xie et al. 2006) \[47\]
                           ifosphamide        Holoxan^®^, Baxter                 0.52--33.33                                 56.63                    16 g/m^2^in 96 h           1827.7                3 g/m^2^/day              (Wright et al. 1995) \[48\] (Boddy et al. 1996) \[45\]
                           chlorambucil       Sigma                              1.302--83.33                                0.49                     0.2 mg/m^2^                0.883                 0.2 mg/m^2^               (GlaxoSmithKline Research Triangle Park) \[49\]
                           streptozotocin     Sigma                              0.65--41.66                                 **¤**                                                                                               
  miscellaneous            asparaginase       Asparaginase Medac, Medac          0.065--4.166\*                              4.48\*                   10000 IU/m^2^              0.943                 30000 IU/m^2^             (Ho et al. 1981) \[50\] (Ylikangas et al. 2002) \[51\]
                           hydroxyurea        Sigma                              0.65--41.66                                 21                       18 mg/kg                   82.49                 15 mg/kg                  (Gwilt et al. 2003) \[52\] (Yan et al. 2005) \[46\]
                           prednisolone       Di-Adreson F Aquosum, Organon      1.56--100                                   0.325                    1 mg/kg/day                1.33                  1 mg/kg/day               (Rostin et al. 1990) \[53\]

**Cmax**: maximum plasma level after administration of the clinical dose of the drug

\*In case of bleomycin and asparaginase concentrations are in IU/ml

**AUC**: area under curve

\#: not used in the clinical practice

¤: no data is available

###### 

The average Mean Cell Survival (MCS) of the 17 LCLs at different drug concentrations, expressed as the Ratio of Maximum Achieved Plasma Concentration (RMAPC)

                                       64× dilution           16× dilution   4× dilution   1× no dilution               64× dilution                    16× dilution   4× dilution   1× no dilution
  ------------- ---------------------- ---------------------- -------------- ------------- ---------------- ----------- ------------------------------- -------------- ------------- ----------------
  **Group 1**   **Vincristine**        **Epirubicin**                                                                                                                                
                **RMAPC**              0.018                  0.071          0.282         1.128            **RMAPC**   0.003                           0.012          0.046         0.184
                **MCS**                81.498                 46.541         20.776        18.995           **MCS**     85.206                          65.736         29.435        16.306
                **SD**                 27.995                 25.737         15.258        12.209           **SD**      15.548                          23.394         13.593        11.314
                                                                                                                                                                                     
                **Paclitaxel**         **Methotrexate**                                                                                                                              
                **RMAPC**              0.020                  0.081          0.326         1.303            **RMAPC**   0.001                           0.004          0.014         0.057
                **MCS**                48.119                 29.999         24.653        23.148           **MCS**     76.618                          44.824         32.924        29.314
                **SD**                 28.435                 17.418         12.869        13.364           **SD**      22.796                          25.843         15.590        16.455
                                                                                                                                                                                     
  **Group 2**   **Gemcitabin**         **Dactinomycin**                                                                                                                              
                **RMAPC**              0.035                  0.140          0.561         2.242            **RMAPC**   0.066                           0.262          1.050         4.200
                **MCS**                49.354                 38.411         27.808        23.784           **MCS**     86.206                          54.700         20.520        16.465
                **SD**                 34.718                 30.034         16.945        12.153           **SD**      16.701                          22.386         13.642        8.370
                                                                                                                                                                                     
                **5-Flurouracil**      **Vinorelbine**                                                                                                                               
                **RMAPC**              0.012                  0.047          0.188         0.752            **RMAPC**   0.156                           0.625          2.501         10.005
                **MCS**                74.861                 58.001         42.337        30.505           **MCS**     82.833                          42.823         25.176        24.683
                **SD**                 23.686                 22.987         21.370        20.645           **SD**      18.131                          23.930         16.506        14.634
                                                                                                                                                                                     
                **Doxorubicin**        **Daunorubicin**                                                                                                                              
                **RMAPC**              0.028                  0.112          0.447         1.789            **RMAPC**   0.133                           0.531          2.126         8.502
                **MCS**                82.503                 52.477         28.292        11.499           **MCS**     83.171                          61.159         25.940        20.439
                **SD**                 21.753                 24.867         22.314        10.301           **SD**      21.886                          25.402         23.933        17.961
                                                                                                                                                                                     
                **Etoposide**          **Docetaxel**                                                                                                                                 
                **RMAPC**              0.130                  0.521          2.083         8.333            **RMAPC**   0.260                           1.042          4.166         16.665
                **MCS**                56.281                 35.375         25.315        16.778           **MCS**     32.990                          23.036         23.866        26.331
                **SD**                 21.045                 19.983         15.497        11.166           **SD**      22.690                          17.587         16.810        19.810
                                                                                                                                                                                     
  **Group 3**   **Cytarabine**         **6-Mercaptopurine**                                                                                                                          
                **RMAPC**              0.121                  0.482          1.929         7.716            **RMAPC**   0.543                           2.170          8.680         34.720
                **MCS**                87.321                 79.450         48.255        40.124           **MCS**     84.450                          78.834         62.325        55.419
                **SD**                 17.396                 22.850         26.423        26.315           **SD**      22.147                          16.514         29.820        32.858
                                                                                                                                                                                     
                **Oxaliplatin**        **Cladribine**                                                                                                                                
                **RMAPC**              0.020                  0.081          0.325         1.301            **RMAPC**   0.366                           1.462          5.850         23.399
                **MCS**                87.951                 84.477         83.331        73.511           **MCS**     102.832                         101.241        72.497        52.237
                **SD**                 21.010                 26.545         21.839        30.744           **SD**      8.130                           11.160         26.804        29.545
                                                                                                                                                                                     
                **Asparaginase**       **Chlorambucil**                                                                                                                              
                **RMAPC**              0.015                  0.058          0.232         0.930            **RMAPC**   2.646                           10.586         42.342        169.370
                **MCS**                92.021                 91.570         90.371        82.978           **MCS**     89.903                          71.879         13.225        11.099
                **SD**                 13.718                 13.222         18.153        15.919           **SD**      17.578                          26.506         10.994        7.527
                                                                                                                                                                                     
                **Cyclophosphamide**   **Topotecan**                                                                                                                                 
                **RMAPC**              0.014                  0.056          0.224         0.896            **RMAPC**   6.194                           24.777         99.107        396.429
                **MCS**                86.670                 93.412         89.498        84.041           **MCS**     93.897                          72.802         23.250        24.784
                **SD**                 21.910                 18.833         17.832        17.920           **SD**      19.406                          21.275         16.659        21.380
                                                                                                                                                                                     
                **Ifosphamide**        **Carboplatin**                                                                                                                               
                **RMAPC**              0.009                  0.037          0.147         0.588            **RMAPC**   2.814                           11.257         45.027        180.108
                **MCS**                92.729                 95.906         90.101        88.518           **MCS**     91.805                          79.175         77.962        52.322
                **SD**                 16.694                 14.965         15.299        16.677           **SD**      16.670                          30.927         22.065        31.295
                                                                                                                                                                                     
                **Hydroxyurea**        **Bleomycin**                                                                                                                                 
                **RMAPC**              0.031                  0.124          0.496         1.984            **RMAPC**   2.078                           8.311          33.245        132.979
                **MCS**                95.118                 96.489         86.340        68.134           **MCS**     90.007                          88.553         82.168        69.803
                **SD**                 19.595                 13.933         19.759        24.782           **SD**      19.294                          17.678         19.720        16.686
                                                                                                                                                                                     
                **Vinblastine**        **Streptozotocin**                                                                                                                            
                **RMAPC**              2.603                  10.413         41.650        166.600          **RMAPC**   no Cmax data was found                                       
                **MCS**                81.507                 53.331         28.885        21.323           **MCS**     95.430                          92.335         89.919        87.805
                **SD**                 25.921                 25.678         17.941        15.889           **SD**      15.828                          18.710         14.094        22.637
                                                                                                                                                                                     
                **Bortezomib**         **MG-132**                                                                                                                                    
                **RMAPC**              0.162                  0.648          2.590         10.361           **RMAPC**   not used in clinical practice                                
                **MCS**                93.119                 81.671         75.498        28.700           **MCS**     87.345                          96.374         88.097        27.045
                **SD**                 13.779                 21.572         19.617        26.948           **SD**      13.980                          17.493         16.974        24.310
                                                                                                                                                                                     
                **Prednisolone**                                                                                                                                                     
                **RMAPC**              4.8                    19.23077       76.92308      307.6923                                                                                  
                **MCS**                75.55877               76.25595       62.46537      37.23379                                                                                  
                **SD**                 4.647172               11.09091       13.97021      11.65414                                                                                  

Group 1. Highly effective drugs: RMAPC \< 0.3; MCS \< 30%

Group 2. Partially effective drugs: RMAPC between 0.3 and 1, MCS \< 60%

Group 3. Ineffective drugs: RMAPC \> 1 or MCS \> 60%

SD: standard deviation in mean cell survival
